Fingerprint
Dive into the research topics of 'Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma'. Together they form a unique fingerprint.
Medicine & Life Sciences
Cutaneous T-Cell Lymphoma
Sezary Syndrome
TOR Serine-Threonine Kinases
Phosphatidylinositol 3-Kinase
Skin
2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one
temsirolimus
70-kDa Ribosomal Protein S6 Kinases
Growth Inhibitors
Mycosis Fungoides
Mechanistic Target of Rapamycin Complex 1
Everolimus
Apoptosis
Proto-Oncogene Proteins c-akt
Gene Dosage
Sirolimus
Chemokines
Heterografts
Therapeutics
Cytokines
Gene Expression
Cell Line
Survival
Chemical Compounds
T-cells
TOR Serine-Threonine Kinases
Phosphatidylinositol 3-Kinase
2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one
temsirolimus
70-kDa Ribosomal Protein S6 Kinases
Growth Inhibitors
Mechanistic Target of Rapamycin Complex 1
Everolimus
Apoptosis
Proto-Oncogene Proteins c-akt
Gene expression
Sirolimus
Tumors
Cells
Chemokines
Heterografts
Genes
Tissue
Cytokines